In another approach, a drug-conjugated TCR-like antibody (Tesirine, SG3249) against TRBC1 was developed, showing that the antibody was internalized by the tumor cells and killed the cells in vitro and in vivo as demonstrated with immunodeficient mice injected with Jurkat TRBC1+ tumor cells. Here, TRBC1 is linked to neoplasm.